Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
9
×
boston top stories
life sciences
national blog main
san francisco blog main
9
×
national top stories
biotech
clinical trials
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
cancer
eli lilly
fda
bristol-myers squibb
fremanezumab
merck
novartis
teva pharmaceutical
alder biopharmaceuticals
allergan
alnylam pharmaceuticals
What
drug
9
×
new
9
×
approval
companies
fda
medicines
approved
bio
cancer
class
disease
drugs
earlier
known
medicine
migraine
nash
roundup
targets
won
year
adds
advantages
alliance
amgen
areas
arguments
bar
big
biogen’s
biopharmaceutical
biosciences
biotech
bio’s
black
brii
brings
candidates
cholesterol
clinic
Language
unset
Current search:
new
×
drug
×
" boston blog main "
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines